Q4 2025 earnings call: 15% revenue growth, $3.9M sales, CapsoCam Colon Gen 2/AI 510(k) timing, trials & funding—read now.
CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the ...
Also on March 16, 2026, CapsoVision decided to halt pursuit of FDA clearance for its first-generation CapsoCam Colon following regulators’ questions on image processing and study design, redirecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results